B. Jensen

发表

THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DESMOPRESSIN: EFFECT ON PLASMA FACTOR VIII C AND VON WILLEBRAND FACTOR

D. Argenti, B. Jensen, D. Heald, 1997, American journal of therapeutics.

Estimating Mass Balance for Inhaled Drugs in Humans: An Example with a VLA‐4 Antagonist, IVL745

B. Jensen, S. Rohatagi, Zhaopie Zeng, 2004, Journal of clinical pharmacology.

Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End‐Stage Renal Insufficiency

S. Waldman, H. Greenberg, B. Boutouyrie, 2000, Journal of clinical pharmacology.

Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler

B. Jensen, S. Newman, S. Rohatagi, 2004, American journal of therapeutics.

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

A. Frick, R. Rosenburg, B. Jensen, 2006, Journal of clinical pharmacology.

Pharmacokinetic‐Pharmacodynamic Modeling of the Antilipolytic Effects of an Adenosine Receptor Agonist in Healthy Volunteers

B. Jensen, S. Rohatagi, P. Zannikos, 2001, Journal of clinical pharmacology.

First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.

E. Braunwald, T. Henry, L. Jennings, 2000, American heart journal.

Pharmacokinetics of Retinoids in Women after Meal Consumption or Vitamin A Supplementation

B. Jensen, P. Heizmann, A. Rakhit, 1996, Journal of clinical pharmacology.

Population Pharmacokinetics and Pharmacodynamics of Ciclesonide

J. Barrett, B. Jensen, R. Nave, 2003, Journal of clinical pharmacology.

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

A. Frick, R. Rosenburg, B. Jensen, 2006, Journal of clinical pharmacology.

The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris.

T. Franz, B. Jensen, L. A. McGann, 1991, Journal of the American Academy of Dermatology.

Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA‐4 Antagonist, HMR1031

B. Jensen, S. Rohatagi, B. Shah, 2003, Journal of clinical pharmacology.

Negligible Systemic Absorption of Topical Isotretinoin Cream: Implications for Teratogenicity

I. Patel, B. Jensen, A. Rakhit, 1997, Journal of clinical pharmacology.

Pharmacokinetics of Acitretin in Humans

B. Jensen, U. Wiegand, 1991 .

Effects of food on the pharmacokinetics of sparfloxacin.

G. Talbot, B. Jensen, M. Dorr, 1999, Clinical therapeutics.

A Mass Balance Study to Evaluate the Biotransformation and Excretion of [14C]‐Triamcinolone Acetonide following Oral Administration

R. Schleimer, D. Argenti, B. Jensen, 2000, Journal of clinical pharmacology.

Pharmacokinetics of Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention With and Without Glycoprotein IIb/IIIa Therapy

D. Argenti, B. Jensen, D. Heald, 2003, American journal of therapeutics.

Pharmacokinetics and Concentration‐Effect Analysis of Intravenous RGD891, a Platelet GPIIb/IIIa Antagonist, Using Mixed‐Effects Modeling (NONMEM)

B. Jensen, G. Rhodes, S. Rohatagi, 2000, Journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers

B. Jensen, S. Rohatagi, P. Zannikos, 2000, Journal of clinical pharmacology.

Food Increases the Bioavailability of Acitretin

P. McNamara, B. Jensen, C. Brindley, 1988, Journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects

B. Jensen, S. Rohatagi, C. Natarajan, 2004, American journal of therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients

B. Jensen, S. Rohatagi, S. Kirkesseli, 2000, Journal of clinical pharmacology.

Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.

B. Jensen, G. Rhodes, S. Rohatagi, 2001, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of sparfloxacin in patients with renal impairment.

T. Marbury, G. Talbot, B. Jensen, 1999, Clinical therapeutics.

The utility of mixed‐effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride

R. Krishna, B. Jensen, A. Sankoh, 2004, Biopharmaceutics & drug disposition.

Mass Balance Study of [14C]M100240, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Male Subjects

B. Jensen, S. Rohatagi, N. Martin, 2003, American journal of therapeutics.

Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers

B. Boutouyrie, B. Jensen, P. Zannikos, 1999, Journal of clinical pharmacology.